FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance InnovationWhite Oak, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced it is sharing information about the agency’s flexible approach to overseeing chemistry, manufacturing and control (CMC) requirements for cell and gene therapies (CGT). The agency’s more flexible approach has been, and is expected to continue to be, helpful in expediting product development and will help guide the FDA’s evaluation of development strategies in preparation for a Biologics License Application (BLA) submission.
Paul Chua Joins Health-ISAC® as Asia Pacific Operations DirectorChua will spearhead Health-ISAC’s expansion into the APAC region, enhancing cybersecurity and resilience in the global health sector
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: Announces Faraday Future’s Outlook for 2026LOS ANGELES, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (
NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today shared a weekly business update from YT Jia, Founder and Global Co-CEO of FF.
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through InnovationRichard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 –
Zymeworks Outlines Strategic Priorities and Outlook for 2026VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significant clinical, operational and financial progress, Zymeworks is focused on executing a long-term strategy designed to maximize value creation for patients, partners, and shareholders.
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for VitiligoNEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML –
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for VitiligoPARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-’408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-‘408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-‘408 trials during 2026.
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue GuidancePreliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million
HealthEx Partners with Anthropic to Turn Patients’ Scattered Medical Records into Actionable Health InsightsHealthEx is the first consumer health record integration for Claude by Anthropic to securely link comprehensive medical histories with user privacy and control
Bitget Listed Lowest Trading Fees Across Major Crypto ExchangesVICTORIA, Seychelles, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Bitget has released a comparative review examining trading fees across leading cryptocurrency exchanges, offering a structured overview of how spot and derivatives trading costs differ among major platforms as global trading activity continues to scale.
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million
Exagen Inc. Announces Select Preliminary 2025 Financial ResultsCARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare ConferenceZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an update on its latest progress, developments plans and expected 2026 milestones, which it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Kepler Successfully Launches First Tranche of Optical Relay SatellitesTORONTO, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Kepler Communications today announced the successful launch of the first tranche of its optical relay satellites aboard a SpaceX Falcon 9 rocket from Vandenberg Space Force Base, California. The satellites will now begin commissioning as Kepler transitions its optical data relay network into operational service.
Commerce Supports Universal Commerce Protocol, Plans to Offer Buying Directly Across Google’s AI SurfacesNew standard creates a common language for agents and systems across the entire shopping journey from discovery and buying to post-purchase experiences
RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial OfficerALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardent HealthFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardent To Contact Him Directly To Discuss Their Options
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026
Tourism Transformation: Hospitality Visionary Invests in College of CharlestonA major gift to the university transforms its hospitality program into the College’s first named school.
Etienna Bio Secures Exclusive Worldwide License from UMass Chan Medical School for Novel Adipose-Derived Regenerative PlatformLEAWOOD, Kan., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled biomaterials for regenerative and aesthetic applications, today announced that it has entered into an exclusive, worldwide license agreement with the UMass Chan Medical School to develop and commercialize a proprietary adipose-derived cellular and matrix technology platform.
RecycLiCo Grants Stock OptionsDELTA, British Columbia, Jan. 09, 2026 (GLOBE NEWSWIRE) -- RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”) (TSX.V: AMY | OTCQB: AMYZF | FSE: ID4), a critical minerals refining and lithium-ion battery upcycling company, announces that the Company has granted an aggregate of 3,000,000 stock options to Rob Chang, director, pursuant to the Company’s omnibus equity incentive plan. The stock options have an exercise price of $0.13 per share and an expiry date of January 8, 2031.
CPNG DEADLINE ALERT: Coupang, Inc. Investors Urged to Contact Kirby McInerney LLP About Class Action LawsuitNEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Coupang, Inc. (“Coupang” or the “Company”) (
NYSE:CPNG) investors of the February 17, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action.
The Bahamas Congratulates Miami Hurricanes on Historic College Football Playoff Run as Official Destination PartnerNassau, The Bahamas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Bahamas Ministry of Tourism, Investments & Aviation (BMOTIA) proudly celebrates its ongoing partnership with the the Miami Hurricanes as their official destination partner, spotlighting the team’s remarkable 2025-2026 football season.
Coastal Financial Corporation Acquires GreenFi Brand, Expanding Strategic FlexibilityEVERETT, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Coastal Financial Corporation (Nasdaq: CCB), the holding company for Coastal Community Bank, today announced that it has acquired ownership of the GreenFi brand of climate-friendly consumer financial services products from Mission Financial Partners.
FIRST WILDFIRE SURVIVOR BREAKS GROUND THROUGH HABITAT LA’S ReBUILD LA PROGRAM—CHOOSING 0% INTEREST OVER PREDATORY LOANSLos Angeles, Jan. 09, 2026 (GLOBE NEWSWIRE) -- WHO: Habitat for Humanity of Greater Los Angeles (Habitat LA) ReBUILD LA Program Homeowner (first family to begin construction)
SLNO Investigation: Investors Encouraged to Contact Kirby McInerney LLPNEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (
NASDAQ:SLNO) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
Cooper Aerobics Partners with The Stayton at Museum WayWellness Center Management & Wellness Programming by Cooper
U.S. Neurology Associates Partners with M33 Growth to Transform Neurological CareDALLAS and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- M33 Growth, a Boston-based venture and growth-stage investment firm, today announced its partnership with U.S. Neurology Associates (“USNA” or the “Company”), a physician services organization dedicated to transforming community-based neurology care. Through this partnership, USNA will serve neurology practices and their patients across a broad spectrum of neurological indications. Nitin Jain will serve as USNA’s Chief Executive Officer and Brad Hively will serve as Chairman and co-founder. Prior to this role, Nitin Jain served as President of Value Based Care for U.S. Renal Care, and Brad Hively served as CEO of The Oncology Institute (
NASDAQ: TOI).
Bleichroeder Acquisition Corp. II Completes $287,500,000 Initial Public OfferingNEW YORK, NY, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bleichroeder Acquisition Corp. II (the “Company”) announced today the closing of its initial public offering of 28,750,000 units, which includes 3,750,000 units issued pursuant to the exercise in full by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $287,500,000.
WEBUY GLOBAL LTD Receives Nasdaq Notification Regarding Minimum Stockholders’ Equity DeficiencySingapore, Jan. 09, 2026 (GLOBE NEWSWIRE) -- WEBUY GLOBAL LTD (Nasdaq: WBUY) (the “Company” or “Webuy”) today announced that the Company received a notice from the staff of the Nasdaq Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that it is not in compliance with the minimum of $2,500,000 in stockholders’ equity for continued listing of the Company’s class A ordinary shares of a par value of US$0.0000462 each (the “Class A Ordinary Shares”) on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Rule”) (the “Notification Letter”).
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025 Earnings Release Date and Conference Call InformationSAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (
NYSE:AAT) (the “Company”) will announce its fourth quarter and year-end 2025 earnings in a press release to be issued after the market closes on Tuesday, February 3, 2026.
Coca-Cola Consolidated, Inc. Announces First Quarter DividendCHARLOTTE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Coca-Cola Consolidated, Inc. (
NASDAQ: COKE) announced that its Board of Directors has declared a dividend for the first quarter of 2026 of $0.25 per share on shares of the Company's Common Stock and Class B Common Stock payable on February 6, 2026, to stockholders of record as of the close of business on January 23, 2026.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on January 2, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 434 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
First Hawaiian to Report Fourth Quarter 2025 Financial Results on January 30, 2026HONOLULU, Jan. 09, 2026 (GLOBE NEWSWIRE) -- First Hawaiian, Inc. (
NASDAQ: FHB) announced today that it plans to release its fourth quarter 2025 financial results on Friday, January 30, 2026 before the market opens. First Hawaiian will host a conference call to discuss the company’s results on the same day at 1:00 p.m. Eastern Time (8:00 a.m. Hawaii Time).
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct OfferingTAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (
NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66,666,666 Class A ordinary shares of the company, no par value per share (the “Shares”) (or pre-funded warrants in lieu thereof), at a purchase price of $0.15 per share in a registered direct offering. The purchase price for each pre-funded warrant is identical to the purchase price for each Share, less the exercise price of $0.001 per share.
AACSB Opens Public Comment on 2026 Global Standards for Business EducationTAMPA, Fla., Jan. 09, 2026 (GLOBE NEWSWIRE) -- AACSB International today released exposure drafts of its inaugural Global Standards for Business Education and 2026 Accounting Accreditation Standards inviting feedback from business schools, faculty, students, employers, higher education associations, and other stakeholders worldwide.
Billie Eilish, Viola Davis, Cathy Hughes, 2Chainz, Clifford ‘TI’ Harris, Robert Smith, Anika Noni Rose, Jamal Roberts, John Hope Bryant and Rev. A.R Bernard, Sr. slated to Join The King Center for the 41st Annual King Holiday ObservanceTheme: Mission Possible 2: Building Community, Uniting A Nation -the Nonviolent Way
UPDATE - OHA Leads Private Debt Financing Supporting Majesco’s Acquisition of VitechNew York, New York, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oak Hill Advisors (“OHA”) served as Administrative Agent and Lead Left Arranger for a private unitranche financing supporting Majesco’s acquisition of Vitech Systems Group (“Vitech”) and a concurrent refinancing. Majesco, a portfolio company of Thoma Bravo, is a leading provider of cloud-native, AI-native software for insurers in the property and casualty (P&C) and life, annuity and health (L&AH) sectors. Vitech is a complementary provider of cloud-native pension and benefits administration software.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Origin Bancorp, Inc. Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference CallRUSTON, La., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Origin Bancorp, Inc. (
NYSE: OBK) (“Origin”), the financial holding company for Origin Bank, plans to issue fourth quarter and full year 2025 results after the market closes on Wednesday, January 28, 2026, and hold a conference call to discuss such results on Thursday, January 29, 2026, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time). The conference call will be hosted by Drake Mills, Chairman, President and CEO of Origin, William J. Wallace, IV, Chief Financial Officer of Origin, and Lance Hall, President and CEO of Origin Bank.
Bosuer Electric Off-Road Innovation Takes the Spotlight at CES 2026LAS VEGAS, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Zhejiang Bosuer Motion Apparatus Co., Ltd. (Bosuer), a manufacturer specializing in electric off-road vehicles and an established electric dirt bike supplier, is presenting its latest electric dirt bike innovations at CES 2026, introducing an expanded and refined lineup aimed at accelerating the electrification of the off-road powersports market. At this year’s show, Bosuer is highlighting four core electric off-road motorcycle models — E60, E72, S6 (ES60), and the newly launched S5 — demonstrating the company’s growing technological depth and product breadth in high-performance electric mobility.
DYWIDAG completes sale of TAM Groupe to Private Assets as plannedMunich, Germany, Jan. 09, 2026 (GLOBE NEWSWIRE) -- On the 31st December 2025, DYWIDAG Systems International (DYWIDAG) completed the sale of 100% of its shares in TAM Groupe (the “Company”), a French market leader in manufacturing and distribution of chemical products, fixing and lifting systems, and accessories for the construction market, to Private Assets SE & Co. KGaA (Private Assets).
Transaction in Own SharesTransaction in Own Shares
STRIDE UGRENT CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Stride, Inc. Investors of the January 12th Deadline and Urges Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Stride (LRN) To Contact Him Directly To Discuss Their Options
FIREFLY URGENT CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urges Firefly Stockholders to Contact the Firm Before January 12th Regarding Their RightsBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Firefly (FLY) To Contact Him Directly To Discuss Their Options
Central Bancompany, Inc. Announces Conference Call to Discuss Fourth Quarter and Full-Year 2025 ResultsJEFFERSON CITY, Mo., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Central Bancompany, Inc. (Nasdaq: CBC) (“Central Bancompany” or “the Company”), the bank holding company for The Central Trust Bank, will release its fourth quarter 2025 financial results before market hours on Tuesday, January 27, 2026. The Company will host a conference call and webcast at 9:00 a.m. CT on Tuesday, January 27, 2026. The call may include discussion of Company developments, forward-looking statements and other material information about business and financial matters.
TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their RightsBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Telix (TLX) To Contact Him Directly To Discuss Their Options
Bright Minds Biosciences Announces Closing of US$175 Million Public OfferingNEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (
NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds.
Banco Santander Chile: Fourth Quarter 2025 Analyst and Investor Webcast / Conference CallSANTIAGO, Chile, Jan. 09, 2026 (GLOBE NEWSWIRE) -- You are cordially invited to participate in Banco Santander Chile's (
NYSE: BSAC) conference call-webcast on Thursday February 5, 2026, at 9.00 AM NY time (11.00am Chile time) where we will discuss 4Q 2025 financial results. The Bank's Officers participating in the conference call are: Patricia Pérez, CFO, Cristian Vicuña, Chief Strategy Officer & Head of IR and Lorena Palomeque, Economist. A question and answer session will follow the presentation.
CN Reports December Grain MovementMONTREAL, Jan. 09, 2026 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (
NYSE: CNI) announced today that it set a new monthly record for grain movement in December, marking its fourth consecutive record month. CN moved over 2.82 million metric tonnes of grain from Western Canada last month, surpassing its previous December record set in 2020 by over 80,000 metric tonnes.
Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare ConferenceDURHAM, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced an updated presentation time of 11:15 am PST on Tuesday, January 13, 2026, at the J.P. Morgan Annual Healthcare Conference (San Francisco).
Cemtrex, Inc. Announces $4 Million Registered Direct OfferingHauppauge, NY, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cemtrex, Inc. (
NASDAQ: CETX) (the “Company”), an advanced security technology and industrial services company, today announced that it has entered into a definitive agreement for the purchase of approximately 1,469,507 shares and / or pre funded warrants with a single institutional investor, at a purchase price of $2.722 per share, with gross proceeds to the Company expected to be $4 million to the Company.
Infinity Home Services Announces CEO TransitionBROOKFIELD, Wis., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Infinity Home Services (IHS), a leading home services platform, today announced a leadership transition designed to support the company’s continued growth and long-term strategy.
FFIV Investors Have Opportunity to Lead F5, Inc. Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES, Jan. 09, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against F5, Inc. (“F5” or “the Company”) (
NASDAQ: FFIV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
